The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Synthetic Biology for Synthetic Chemistry
Abstract
The richness and versatility of biological systems make them ideally suited to solve some of the world's most significant challenges, such as converting cheap, renewable resources into energy-rich molecules; producing high-quality, inexpensive drugs to fight disease; and remediating polluted sites. Over the years, significant strides have been made in engineering microorganisms to produce fuels, bulk chemicals, and valuable drugs from inexpensive starting materials; to detect and degrade nerve agents as well as less toxic organic pollutants; and to accumulate metals and reduce radionuclides. The components needed to engineer the chemistry inside a microbial cell are significantly different from those commonly used to overproduce pharmaceutical proteins. Synthetic biology has had and will continue to have a significant impact on the development of these components to engineer cellular metabolism and microbial chassis to host the chemistry. The ready availability of more well-characterized gene expression components and hosts for chemical synthesis, standards for the connection of these components to make larger functioning devices, computer-aided design software, and debugging tools for biological designs will decrease both the time and the support needed to construct these designs. Some of the most important tools for engineering bacterial metabolism and their use for production of the antimalarial drug artemisinin are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., et al. (2006) · Nature · doi:10.1038/nature04640 · Cited by 2,805
Self-citationEngineering Escherichia coli for production of functionalized terpenoids using plant P450s
Chang, M. C. Y., Eachus, R. A., Trieu, W., Ro, D.-K., & Keasling, J. D. (2007) · Nature Chemical Biology · doi:10.1038/nchembio875 · Cited by 364
Self-citationSchmid, G., & Hofheinz, W. (1983) · Journal of the American Chemical Society · doi:10.1021/ja00341a054 · Cited by 329 · cited 1×
“Although total synthesis of artemisinin is difficult and costly (115), the semisynthesis of artemisinin or any derivative”
BackgroundMercke, P., Bengtsson, M., Bouwmeester, H. J., Posthumus, M. A., & Brodelius, P. E. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1962 · Cited by 283
Newman, J. D., Marshall, J., Chang, M., Nowroozi, F., Paradise, E., Pitera, D., Newman, K. L., & Keasling, J. D. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21017 · Cited by 257 · cited 1×
“) Production of amorphadiene from the imported mevalonate pathway was found to be substantially higher than production obtained with a supplemental DXP pathway (121), yielding titers of 280 mg L 1 after 24 h or 480 mg L 1 in a fed-batch bioreactor (127).”
BackgroundKorenromp, E. L., Williams, B. G., Gouws, E., Dye, C., & Snow, R. W. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00657-1 · Cited by 245
Chang, Y.-J., Song, S.-H., Park, S.-H., & Kim, S.-U. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2061 · Cited by 154
A simple conversion of artemisinic acid into artemisinin
Roth, R. J., & Acton, N. (1989) · Journal of Natural Products · doi:10.1021/np50065a050 · Cited by 136 · cited 1×
“coli was further engineered to produce artemisinic acid, which can be converted directly into the antimalarial drug artemisinin in two chemical steps (Figure 3) (130).”
BackgroundImpact of ‘ome’ analyses on inverse metabolic engineering
Bro, C., & Nielsen, J. (2004) · Metabolic Engineering · doi:10.1016/j.ymben.2003.11.005 · Cited by 116
On the conversion of dihydroartemisinic acid into artemisinin
Acton, N., & Roth, R. J. (1992) · The Journal of Organic Chemistry · doi:10.1021/jo00039a020 · Cited by 103 · cited 1×
“friendly, high quality, and reliable (116, 117).”
Source of New Hope Against Malaria is in Short Supply
Enserink, M. (2005) · Science · doi:10.1126/science.307.5706.33 · Cited by 85
Cited by
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
Ultrahigh-throughput screening in drop-based microfluidics for directed evolution
Agresti, J. J., Antipov, E., Abate, A. R., Ahn, K., Rowat, A. C., Baret, J.-C., Marquez, M., Klibanov, A. M., Griffiths, A. D., & Weitz, D. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910781107 · Cited by 1,149
Engineering microbial consortia: a new frontier in synthetic biology
Brenner, K., You, L., & Arnold, F. H. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.05.004 · Cited by 1,018
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Polyhydroxyalkanoates: Characteristics, production, recent developments and applications
Raza, Z. A., Abid, S., & Banat, I. M. (2018) · International Biodeterioration & Biodegradation · doi:10.1016/j.ibiod.2017.10.001 · Cited by 708
Metadata
- Authors
- Keasling, J. D.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 64-76
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2051539600
- Cited by
- 409
- References
- 11
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.